Marbou Takougoum Jean W, Whiteside Samantha A, Carroll Daelyn G, Mohiuddin Mahi M, Bronner Stéphane, Binda Sylvie, Creuzenet Carole
Microbiology and Immunology, The University of Western Ontario, London, ON, Canada.
Lallemand Health Solutions, Rosell Institute for Microbiome and Probiotics, Montreal, Quebec, Canada.
Methods Mol Biol. 2025;2942:63-79. doi: 10.1007/978-1-0716-4627-4_6.
Helicobacter pylori (HP) is a chronic bacterial pathogen that can cause gastric ulcers and cancers. The treatment for HP infections relies on a combination of antibiotics and proton pump inhibitors. Due to rising antibiotic resistance, curtailing HP-induced diseases requires identifying new anti-HP molecules that can reduce HP viability or impair its virulence, including its ability to cause inflammation. Oral intake of lactic acid bacteria (LAB) was shown to enhance the treatment of HP infection, and we demonstrated that LAB secretions can affect HP's growth and virulence factor production. This article describes a panel of in vitro assays that can be used to screen the anti-HP properties of multiple LAB secretions for the identification of novel anti-HP agents. The assays pertain to effects on viability, motility, urease production, and ability to elicit inflammation in gastric cells.
幽门螺杆菌（HP）是一种慢性细菌病原体，可导致胃溃疡和癌症。幽门螺杆菌感染的治疗依赖于抗生素和质子泵抑制剂的联合使用。由于抗生素耐药性不断上升，减少幽门螺杆菌引起的疾病需要识别新的抗幽门螺杆菌分子，这些分子可以降低幽门螺杆菌的活力或削弱其毒力，包括其引发炎症的能力。口服乳酸菌（LAB）已被证明可增强幽门螺杆菌感染的治疗效果，并且我们证明乳酸菌分泌物可影响幽门螺杆菌的生长和毒力因子产生。本文描述了一组体外试验，可用于筛选多种乳酸菌分泌物的抗幽门螺杆菌特性，以鉴定新型抗幽门螺杆菌药物。这些试验涉及对活力、运动性、尿素酶产生以及在胃细胞中引发炎症能力的影响。
